Castellani Beatrice, Eleuteri Michela, Di Bona Stefano, Cruciani Gabriele, Desantis Jenny, Goracci Laura
Molecular Horizon s.r.l., Bettona 06084, Italy.
Department of Chemistry, Biology and Biotechnology, University of Perugia, Perugia 06123, Italy.
J Med Chem. 2023 Sep 28;66(18):13148-13171. doi: 10.1021/acs.jmedchem.3c01144. Epub 2023 Sep 12.
PROteolysis TArgeting Chimeras (PROTACs) are tripartite molecules consisting of a linker connecting a ligand for a protein of interest to an E3 ligase recruiter, whose rationale relies on proteasome-based protein degradation. PROTACs have expanded as a therapeutic strategy to open new avenues for unmet medical needs. Leveraging our expertise, we undertook a series of experiments aimed at elucidating PROTAC metabolism. In particular, we focused on PROTACs recruiting the von Hippel-Lindau (VHL) E3 ligase. After high-resolution mass spectrometry measurements, a characteristic metabolite with mass reduction of 200 units was detected and successively confirmed as a product deriving from the cleavage of the VHL ligand moiety. Subsequently, we identified hepatic and extrahepatic prolyl endopeptidases as the main putative metabolic enzymes involved. Finally, we designed and synthesized analogs of the VHL ligands that we further exploited for the synthesis of novel VHL-directed PROTACs with an improved metabolic stability in applications.
蛋白酶靶向嵌合体(PROTACs)是由连接感兴趣蛋白质配体与E3连接酶招募剂的接头组成的三方分子,其原理依赖于基于蛋白酶体的蛋白质降解。PROTACs已发展成为一种治疗策略,为未满足的医疗需求开辟了新途径。利用我们的专业知识,我们进行了一系列旨在阐明PROTAC代谢的实验。特别是,我们专注于招募冯·希佩尔-林道(VHL)E3连接酶的PROTACs。经过高分辨率质谱测量,检测到一种质量减少200单位的特征性代谢物,并相继确认为源自VHL配体部分裂解的产物。随后,我们确定肝和肝外脯氨酰内肽酶是主要的推定代谢酶。最后,我们设计并合成了VHL配体的类似物,进一步用于合成在应用中具有改善代谢稳定性的新型VHL导向PROTACs。